Join the club for FREE to access the whole archive and other member benefits.


Developing a broad pipeline of therapies to extend human healthspan and lifespan

We’re an interdisciplinary team of computational biologists, experimental scientists, and seasoned drug hunters. We share the vision that targeting aging directly, rather than targeting individual age-related diseases one at a time, will have a dramatic positive impact on human health.

The BIOAGE discovery platform leverages recent technological advances to create a deep omics map of human aging. We generate this map by applying novel machine learning and bioinformatics approaches to proprietary human cohort data to reveal the molecular drivers of age-related pathology. Our pipeline of therapies targeting these key pathways will address the significant unmet medical needs of an aging population.

At BIOAGE, we are mapping human aging from the ground up. We have forged partnerships with unique biobanks containing healthy human samples collected over decades that are paired with extensive follow-up records that include detailed future healthspan, lifespan, and disease outcomes. We are building deep molecular profiles of these samples, incorporating proteomics, metabolomics, and transcriptomics to identify the best drug targets for healthy aging.

Visit website:



Details last updated 28-Feb-2020

BIOAGE is also referenced in the following:

ARDD 2021 - 8th Aging Research and Drug Discovery Meeting

31-Aug-2021 to 03-Sep-2021

Online event about latest progress in the molecular, cellular and organismal basis of aging organized by University of Copenhagen chaired by Morten Scheibye-Knudsen, Daniela Bakula and Alex Zhavoronkov, and with many speakers.

Hacking your health

BBC Click meets biohackers and companies who believe it will be possible to live on to well beyond 100

People at BIOAGE

Victor Björk

Business Development Professional at the Longevity Biotech

Kristen Fortney

Chief Executive Officer and co-founder at BioAge

Peng Leong

Chief Business Officer and Head of Brain Aging at BioAge Labs

Chris Patil

Biologist of aging, VP-Media at BioAge Labs

Eric Morgen

COO and Co-founder at BioAge Labs

Paul Rubin

Chief Medical Officer at Bioage Labs and Pharma and biotech Consultant at Rubin Pharma.


Drug company BioAge raised $170 million to make new medicines for obesity

Longevity Technology - 13-Feb-2024

Their main drug, azelaprag, is like a pill that mimics the benefits of exercise

Read more... summarises the proceedings of the Buck Institute's Longevity Summit (LEAF) - 20-Jan-2023

Another reminder of the amount of research, with multiple approaches, about to go into clinical trials


Longevity Technology speaks to BioAge's CEO about clinical trial progress

Longevity Technology - 06-Jan-2023

Had success in reducing muscle atrophy and discovered novel class of molecules to target cognitive decline


Bioage licenses new drugs to treat ageing and age-related diseases (LEAF) - 28-Apr-2021

Raised $90M in series C funding - off to a great start initiating three clinical trials


BioAge's anti-ageing drug to treat Covid-19 enters phase 2 trial

Longevity Technology - 22-Mar-2021

Reverses immune ageing and can prevent death from coronavirus infection in the elderly


Bioage's lead therapies moved closer to the clinic

Longevity Technology - 03-Dec-2020

Lead therapies of BioAge to treat age related diseases enter phase 2 trials


Why people should take up a career in the aging research industry (LEAF) - 26-Feb-2020

I think Victor is right, anti-aging is going to be the next big thing

Topics mentioned on this page:
Ageing Research, AI in Healthcare